ATE286072T1 - Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate - Google Patents

Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate

Info

Publication number
ATE286072T1
ATE286072T1 AT01941526T AT01941526T ATE286072T1 AT E286072 T1 ATE286072 T1 AT E286072T1 AT 01941526 T AT01941526 T AT 01941526T AT 01941526 T AT01941526 T AT 01941526T AT E286072 T1 ATE286072 T1 AT E286072T1
Authority
AT
Austria
Prior art keywords
amyloid
amyloid beta
immune response
homologue
induce
Prior art date
Application number
AT01941526T
Other languages
German (de)
English (en)
Inventor
Blas Frangione
Thomas Wisniewski
Einar M Sigurdsson
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of ATE286072T1 publication Critical patent/ATE286072T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01941526T 2000-05-22 2001-05-22 Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate ATE286072T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20557800P 2000-05-22 2000-05-22
PCT/US2001/016322 WO2001090182A2 (en) 2000-05-22 2001-05-22 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits

Publications (1)

Publication Number Publication Date
ATE286072T1 true ATE286072T1 (de) 2005-01-15

Family

ID=22762767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01941526T ATE286072T1 (de) 2000-05-22 2001-05-22 Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate

Country Status (14)

Country Link
US (3) US6713450B2 (https=)
EP (1) EP1284998B1 (https=)
JP (1) JP2003534351A (https=)
CN (1) CN1249085C (https=)
AT (1) ATE286072T1 (https=)
AU (2) AU2001274873B2 (https=)
CA (1) CA2408925A1 (https=)
DE (1) DE60108111T2 (https=)
ES (1) ES2238049T3 (https=)
IL (2) IL152625A0 (https=)
NZ (1) NZ521939A (https=)
PT (1) PT1284998E (https=)
WO (1) WO2001090182A2 (https=)
ZA (1) ZA200207992B (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7148324B1 (en) * 1998-12-14 2006-12-12 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
JP5025871B2 (ja) * 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
AU783144B2 (en) * 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7097837B2 (en) * 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
US20040191264A1 (en) * 2001-02-19 2004-09-30 Nielsen Klaus Gregorius Synthetic vaccine agents
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
AU2002254328A1 (en) * 2001-03-20 2002-10-03 University Of Chicago Inhibitors and disassemblers of fibrillogenesis
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
EP1572894B1 (en) * 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040091945A1 (en) * 2002-07-17 2004-05-13 Cheryl Fitzer-Attas Peptides and methods of screening immunogenic peptide vaccines against Alzheimer's Disease
AU2003298475A1 (en) * 2002-11-14 2004-06-18 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
AU2003303198A1 (en) * 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB0310270D0 (en) * 2003-05-03 2003-06-11 Univ Edinburgh Biomolecular devices
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP4696079B2 (ja) 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
KR20070100234A (ko) * 2004-10-06 2007-10-10 히로시 모리 변이형 아밀로이드 단백질
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
CA2589017A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
MX2007013725A (es) 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) * 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
AU2007284656A1 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
WO2008021296A2 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of alzheimer's disease
US8188046B2 (en) 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008099917A1 (ja) * 2007-02-15 2008-08-21 Fukuoka University 抗hmgb-1抗体を含む臓器移植拒絶抑制剤
JP5225109B2 (ja) * 2007-02-15 2013-07-03 国立大学法人 熊本大学 ヒトｈｍｇｂ−１に特異的に結合する抗体を有効成分として含有する治療剤
US20100216977A1 (en) * 2007-02-15 2010-08-26 Kyushu University, National University Corporation Therapeutic agent for interstitial pulmonary disease comprising anti-hmgb-1 antibody
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US20080292625A1 (en) * 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2207568B1 (en) 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
CN102112488A (zh) * 2008-07-01 2011-06-29 由卫生福利和体育大臣代表的荷兰王国 抗淀粉样折叠中间体的疫苗
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
TWI508976B (zh) * 2009-04-21 2015-11-21 Univ Rockefeller 對β－類澱粉蛋白之基原纖維形式具專一性之抗體
WO2010129674A2 (en) 2009-05-05 2010-11-11 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
CN106390107B (zh) * 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
CN101920008B (zh) * 2009-06-15 2013-07-31 浙江仙琚制药股份有限公司 包含Aβ40多肽和铝佐剂的制剂以及纯化Aβ40多肽的方法
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2013013056A1 (en) 2011-07-19 2013-01-24 New York University Method for treating amyloid disease
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
WO2018038973A1 (en) * 2016-08-20 2018-03-01 The Arizona Board Of Regents On Behalf Of The University Of Arizona Neuroprotective beta amyloid core peptides and peptidomimetic derivatives
EP4486389A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate comprising at least a beta-glucan
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ－グルカン若しくはマンナンからなるか、又はこれを含む結合体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031996A1 (en) * 1994-05-25 1995-11-30 Milkhaus Lab Materials and methods for treatment of plaquing diseases
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
EP1033998B1 (en) 1997-12-03 2005-10-19 Neuralab, Ltd. Suppressing beta-amyloid-related changes in alzheimer's disease

Also Published As

Publication number Publication date
EP1284998B1 (en) 2004-12-29
US7427655B2 (en) 2008-09-23
WO2001090182A2 (en) 2001-11-29
NZ521939A (en) 2004-04-30
US20090081204A1 (en) 2009-03-26
ZA200207992B (en) 2003-07-02
DE60108111D1 (de) 2005-02-03
JP2003534351A (ja) 2003-11-18
CN1249085C (zh) 2006-04-05
EP1284998A2 (en) 2003-02-26
IL152625A (en) 2009-12-24
PT1284998E (pt) 2005-06-30
US20020077288A1 (en) 2002-06-20
US7700107B2 (en) 2010-04-20
WO2001090182A3 (en) 2002-05-23
US20040043935A1 (en) 2004-03-04
US6713450B2 (en) 2004-03-30
DE60108111T2 (de) 2005-12-08
CN1444598A (zh) 2003-09-24
ES2238049T3 (es) 2005-08-16
IL152625A0 (en) 2003-06-24
CA2408925A1 (en) 2001-11-29
AU2001274873B2 (en) 2006-10-05
AU7487301A (en) 2001-12-03

Similar Documents

Publication Publication Date Title
ATE286072T1 (de) Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
BR9610262A (pt) Compostos e métodos para a imunoterapia e diagnose de tuberculose
EP2172551A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
AR036160A1 (es) Regulacion de las vias metabolicas lipidicas en las plantas, mediante transgenesis con sentido o antisentido de factores de transcripcion hap2, hap5 y hap3/lec1
DE60045394D1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
NO20005672L (no) Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet
ES2062437T3 (es) Nueva forma farmaceutica porosa y su preparacion.
WO2002024739A3 (en) Spas-1 cancer antigen
DE60040410D1 (de) Synthetische fasern und zement-basiertes system mit solchen fasern
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
ATE201446T1 (de) Impfstoff gegen geflügelkokzidose
DE602004006493D1 (de) Verfahren und zusammensetzungen zur bildung einer schützenden immunantwort gegen malaria
NO20022147L (no) Mimetiske peptider for epitope av apolipoprotein B-100, konkatamer og modifiserte peptider derav, og vaksinesammensetningsom omfatter det samme
ATE471156T1 (de) Antigene zusammensetzungen zur immunisierung nichtmenschlicher säuger gegen streptococcus equi
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
BR9911388A (pt) Imunógeno de somatostatina sintético para promoção de crescimento em animais de fazenda
IL126250A0 (en) Antibodies against avirulence or pathogenicity proteins of plant pathogens
IT1286829B1 (it) Plasmidi contenenti due o piu' competitori disposti in successione e loro uso in tecniche di pcr-competitiva
DE60036705D1 (de) Adjuvanskombinationen zur immunisierung und vakzine
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium
DE602004011917D1 (de) Verfahren zur herstellung von 4,10 beta-diacetoxy-2 alpha- benzoyloxy-5 beta, 20-epoxy-1,13 alpha-dihydroxy-9-oxo-19- norcyclopropaäg ütax-11-en

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1284998

Country of ref document: EP

REN Ceased due to non-payment of the annual fee